Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses

Molecular Therapy

Volumn 16, Issue 9, 2008, Pages 1546-1555

  Otsuki, Akihiro ^a   Patel, Ankita ^a   Kasai, Kazue ^a   Suzuki, Masataka ^a   Kurozumi, Kazuhiko ^a   Chiocca, E Antonio ^a   Saeki, Yoshinaga ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APHA COMPOUND 8; BUTYRIC ACID; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; INTERFERON; ONCOLYTIC HERPES VIRUS; ONCOLYTIC VIRUS; RHSVQ1; RQNESTIN34.5; TRICHOSTATIN A; VALPROIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; GENETIC TRANSCRIPTION; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; TUMOR XENOGRAFT; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BUTYRATES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; GENE THERAPY; GENETIC VECTORS; GLIOMA; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 1, HUMAN; HISTONE DEACETYLASES; HUMANS; INTERFERON-BETA; MELANOMA; MICE; MICE, NUDE; ONCOLYTIC VIRUSES; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED; VALPROIC ACID; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

HERPES; SIMPLEXVIRUS;

EID: 50549097330     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.155     Document Type: Article

References (50)

1. Chiocca, EA (2002). Oncolytic viruses. Nat Rev Cancer 2: 939-950.
2. Parato, KA, Senger, D, Forsyth, PA and Bell, JC (2005). Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 5: 965-976.
3. Jyminski, E, Leroy, S, Terada, K, Finkelstein, DM, Hyatt, JL, Danks, MK et al. (2005). Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan. Cancer Res 65: 6850-6857.
4. Ferada, K, Wakimoto, H, Tyminski, E, Chiocca, EA and Saeki, Y (2006). Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Ther 13: 705-714.
5. Varghese, S and Rabkin, SD (2002). Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 9: 967-978.
6. Kambara, H, Okano, H, Chiocca, EA and Saeki, Y (2005). An oncolyhc HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 65: 2832-2839.
7. Lee, J, Kotliarova, S, Kodiarov, Y, Li, A, Su, Q, Donin, NM et al. (2006). Tumor stem cells derived from giloblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9: 391-403.
8. Singh, SK, Clarke, ID, Terasaki, M, Bonn, VE, Hawkins, C, Squire, J et al. (2003). Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828.
9. Singh, SK, Hawkins, C, Clarke, ID, Squire, JA, Bayani, J, Hide, T et al. (2004). Identification of human brain tumour initiating cells. Nature 432: 396-401.
10. Phillips, HS, Kharbanda, S, Chen, R, Forrest, WF, Soriano, RH, Wu, TD et al. (2006). Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157-173.
11. Katze, MG, He, Y and Gale, M Jr (2002). Viruses and interferon: A fight for supremacy. Nat Rev Immunol 2: 675-687.
12. Ellermann-Eriksen, S (2005). Macrophages and cytokines in the early defence against herpes simplex virus. Virol J 12: 59.
13. Suzuki, M, Chiocca, EA and Saeki, Y (2007). Early STAT1 activation after systemic delivery of HSV amplicon vectors suppresses transcription of the vector-encoded transgene. Mol Ther 15: 2017-2026.
14. Ikeda, K, Ichikawa, T, Wakimoto, H, Silver, JS, Deisboeck, TS, Finkelstein, D et al. (1999). Oncolytic virus therapy of multiple tumors In the brain requires suppression of innate and elicited antiviral responses. Nat Med 5: 881-887.
15. Wakimoto, H, Fuki, G, Tyminski, E and Chiocca, EA (2004). Altered expression of antiviral cytoldne mRNAs associated with cyclophosphamide's enhancement of viral oncolysis. Gene Ther 11 214-223.
16. Lamfers, ML, Fulci, G, Gianni, D, Tang, Y, Kurozumi, K, Kaur, B et al. (2006). Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Mol Ther 14: 779-788.
17. Ungerechts, G, Springfeld, C, Frenzke, ME, Lampe, J, Parker WB, Sorscher, EJ et al. (2007). An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol Ther 15 1991-1997.
18. Fulci, G, Breymann, L, Gianni, ID, Kurozomi, K, Rhee, SS, Yu, J et al. (2006). Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci USA 103 12873-12878.
19. Kambara, H, Saeki, Y and Chiocca, EA (2005). Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus. Cancer Res 65: 11255-11258.
20. Glozak, MA and Seto, E (2007). Histone deacetylases and cancer. Oncogene 26: 5420-5432.
21. Fouladi, M (2006). Histone deacetylase inhibitors in cancer therapy. Cancer Invest 24: 521-527.
22. Marks, P, Rifkind, RA, Richon, VM, Breslow, R, Miller, T and Kelly, WK (2001). Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 1: 194-202.
23. Chen, WY, Bailey, EC, McCune, SL, Dong, JY and Townes, TM (1997). Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase. Proc Natl Acad Sci USA 94: 5798-5803.
24. Dion, LD, Goldsmith, KT, Tang, DC, Engler, JA, Yoshida, M and Garver, RI Jr (1997). Amplification of recombinant adenoviral transgene products occurs by inhibition of histone deacetylase. Virology 231: 201-209.
25. Yamano, T, Ura, K, Morishita, R, Nakajima, H, Monden, M and Kaneda, Y (2000). Amplification of transgene expression in vitro and in vivo using a novel inhibitor of histone deacetylase. Mol Ther 1: 574-580.
26. Chang, HM, Paulson, M, Holko, M, Rice, CM, Williams, BR, Marie, I et al. (2004). Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc Natl Acad Sci USA 101: 9578-9583.
27. Nusinzon, I and Horvath, CM (2003). Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc Natl Acad Sci USA 100: 14742-14747.
28. Aasakova, J, Novakova, Z, Rossmeislova, L, Kahle, M, Hozak, P and Hodny, Z (2007). Histone deacetylase inhibitors suppress IFNalpha-induced up-regulation of promyelocytic leukemia protein. Blood 109: 1373-1380.
29. Yamamoto, S, Deckter, LA, Kasai, K, Chiocca, EA and Saeki, Y (2006). Imaging immedlate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors. Gene Ther 13: 1731-1736.
30. Wakimoto, H, Johnson, PR, Knipe, DM and Chiocca, EA (2003). Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther 10: 983-990.
31. Haralambieva, I, Iankov, I, Hasegawa, K, Harvey, M, Russell, SJ and Peng, KW (2007). Engineering oncolytic measles virus to circumvent the intracellular innate immune response. Mol Ther 15: 588-597.
32. Kurozumi, K, Hardcastle, J, Thakur, R, Yang, M, Christoforidis, G, Fulci, G et al (2007). Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 99: 1768-1781.
33. McKee, TD, Grandi, P, Mok, W, Alexandrakis, G, Insin, N, Zimmer, JP et al. (2006). Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res 66 2509-2513.
34. Mok, W, Boucher, Y and Jain, RK (2007). Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus. Cancer Res 67: 10664-10668.
35. Chou, J and Roizman, B (1994). Herpes simplex virus 1 gamma(1)34.5 gene function, which blocks the host response to infection, maps in the homologous domain of the genes expressed during growth arrest and DNA damage. Proc Natl Acad Sci USA 91: 5247-5251.
36. He, B, Chou, J, Liebermann, DA, Hoffman, B and Roizman, B (1996). The carboxyl terminus of the murine MyD116 gene substitutes for the corresponding domain of the gamma(1)34.5 gene of herpes simplex virus to preclude the premature shutoff of total protein synthesis in infected human cells. J Virol 70: 84-90.
37. Orvedahl, A, Alexander, D, Talloczy, Z, Sun, Q, Wei, Y, Zhang, W et al. (2007). HSV-1 ICP34.5 confers neurovirulence by targeting the Beclin 1 autophagy protein. Cell Host Microbe 1: 23-35.
38. Chung, RY, Saeki, Y and Chiocca, EA (1999). B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells. J Virol 73: 7556-7564.
39. Entin-Meer, M, Rephaeli, A, Yang, X, Nudelman, A, VandenBerg, SR, Haas-Kogan, DA (2005). Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radlosensitizing capacity in the treatment of malignant gliomas. Mol Cancer Ther 4: 1952-1961.
40. Eyupoglu, IY, Hahnen, E, Trankle, C, Savaskan, NE, Siebzehnrubl, FA Buslei, R et al. (2006). Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275. Mol Cancer Ther 5: 1248-1255.
41. Ugur, HC, Ramakrishna, N, Bello, L, Menon, LG, Kim, SK, Black, PM et al. (2007). Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model. J Neurooncol 83: 267-275.
42. Khodarev, NN, Beckett, M. Labay, E, Darga, T, Roizman, B and Weichselbaum, RR (2004). STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc Natl Acad Sci USA 101: 1714-1719.
43. Bieler, A, Mantwill, K, Dravits, T, Bernshausen, A, Glockzin, G, Kohler-Vargas, N et al. (2006). Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: Histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520. Hum Gene Ther 17: 55-70.
44. Höti, N, Chowdhury, W, Hsieh, JT, Sachs, MD, Lupold, SE, Rodriguez, R (2006). Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy. Mol Ther 14: 768-778.
45. Watanabe, T, Hiokl, M, Fujiwara, T, Nishizaki, M, Kagawa, S, Taki, M et al. (2006). Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells. Exp Cell Res 312: 256-265.
46. Liu, TC, Castelo-Branco, P, Rabkin, SD and Martuza, RL (2008). Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects. Mol Ther 16: 1041-1047.
47. Atmaca, A, Al-Batran, SE, Maurer, A, Neumann, A, Heinzel, T, Hentsch, B et al. (2007). Valproic acid (VPA) in patients with refractory advanced cancer: A dose escalating phase I clinical trial. Br J Cancer 97: 177-182.
48. Lesinski, GB, Anghelina, M, Zimmerer, J, Bakalakos, T, Badgwell, B, Parihar, R et al. (2003). The antitumor effects of IFN-alpha are abrogated in a STATI-deficient mouse. J Clin Invest 112: 170-180.
49. Nagane, M, Coufal, F, Lin, H, Bogler, O, Cavenee, WK and Huang, HJ (1996). A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56: 5079-5086.
50. Ichikawa, T, Hogemann, D, Saeki, Y, Tyminski, E, Terada, K, Weissleder, R et al. (2002). MRI of transgene expression: Correlation to therapeutic gene expression. Neoplasia 4: 523-530.